CD47-targeting antibodies as a novel therapeutic strategy in hematologic malignancies.

Abstract

CD47 is a surface glycoprotein expressed by host cells to impede phagocytosis upon binding to macrophage SIRPα, thereby represents an immune checkpoint known as the "don't-eat-me" signal. However, accumulating evidence shows that solid and hematologic tumor cells overexpress CD47 to escape immune surveillance. Thus, targeting the CD47-SIRPa axis by limiting the activity of this checkpoint has emerged as a key area of research. In this review, we will provide an update on the landscape of CD47-targeting antibodies for hematological malignancies, including monoclonal and bi-specific antibodies, with a special emphasis on agents in clinical trials and novel approaches to overcome toxicity.

• Authors: Jennifer Sun, Yixuan Chen, Berit Lubben, Ola Adebayo, Barbara Muz, Abdel Kareem Azab
• Journal: Leukemia research reports (Leuk Res Rep) Vol. 16 Pg. 100268 ( 2021) ISSN: 2213-0489 [Print] England
• PMID: 34584838 (Publication Type: Journal Article, Review)
• Copyright: © 2021 The Authors. Published by Elsevier Ltd.